BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 9679792)

  • 21. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose--a meta-analysis.
    Perret-Guillaume C; Wahl DG
    Thromb Haemost; 2004 Feb; 91(2):394-402. PubMed ID: 14961170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy.
    Takarada K; Sato M; Goto M; Saito A; Ikeda Y; Fujita S; Fuse K; Takahashi M; Oguro T; Matsushita H; Kitazawa H; Okabe M; Abe H; Toba K; Yamashina A; Aizawa Y
    J Cardiol; 2014 Aug; 64(2):127-32. PubMed ID: 24440439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroke Prevention in Atrial Fibrillation Study. Final results.
    Circulation; 1991 Aug; 84(2):527-39. PubMed ID: 1860198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of thromboembolic events in atrial fibrillation.
    Koefoed BG; Gulløv AL; Petersen P
    Thromb Haemost; 1997 Jul; 78(1):377-81. PubMed ID: 9198182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    Lopes RD; Li L; Granger CB; Wang TY; Foody JM; Funk M; Peterson ED; Alexander KP
    Am J Med; 2012 Sep; 125(9):897-905. PubMed ID: 22795814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation.
    Hess CN; Peterson ED; Peng SA; de Lemos JA; Fosbol EL; Thomas L; Bhatt DL; Saucedo JF; Wang TY
    J Am Coll Cardiol; 2015 Aug; 66(6):616-27. PubMed ID: 26248987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Alexander JH; Lopes RD; Thomas L; Alings M; Atar D; Aylward P; Goto S; Hanna M; Huber K; Husted S; Lewis BS; McMurray JJ; Pais P; Pouleur H; Steg PG; Verheugt FW; Wojdyla DM; Granger CB; Wallentin L
    Eur Heart J; 2014 Jan; 35(4):224-32. PubMed ID: 24144788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary prevention of stroke in patients with nonvalvular atrial fibrillation: optimal intensity of anticoagulation.
    Yasaka M; Yamaguchi T
    CNS Drugs; 2001; 15(8):623-31. PubMed ID: 11524034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation.
    Yasaka M; Minematsu K; Yamaguchi T
    Intern Med; 2001 Dec; 40(12):1183-8. PubMed ID: 11813841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet; 1993 Nov; 342(8882):1255-62. PubMed ID: 7901582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.
    Hylek EM; Skates SJ; Sheehan MA; Singer DE
    N Engl J Med; 1996 Aug; 335(8):540-6. PubMed ID: 8678931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.
    Hart RG; Benavente O; McBride R; Pearce LA
    Ann Intern Med; 1999 Oct; 131(7):492-501. PubMed ID: 10507957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.
    Fang MC; Chang Y; Hylek EM; Rosand J; Greenberg SM; Go AS; Singer DE
    Ann Intern Med; 2004 Nov; 141(10):745-52. PubMed ID: 15545674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group.
    Yamaguchi T
    Stroke; 2000 Apr; 31(4):817-21. PubMed ID: 10753981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications.
    Liu X; Huang H; Yu J; Cao G; Feng L; Xu Q; Zhang S; Zhou M; Li Y
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):454-9. PubMed ID: 24755126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.
    Yu AYX; Malo S; Svenson LW; Wilton SB; Hill MD
    J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29080863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation.
    Gage BF; Cardinalli AB; Owens DK
    Stroke; 1998 Jun; 29(6):1083-91. PubMed ID: 9626276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.